Jin Lu
Peking University People's Hospital · Chinese Academy of Medical Sciences Hospital of Skin Disease · Department of Pediatrics, Peking University People's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jin Lu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:52 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07878351 · Prospective ctDNA Testing in Large B-Cell LymphomaPeking University People's Hospital · recruiting · Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma · principal investigator
- Ph1/Ph2NCT07421856 · Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.Hebei Senlang Biotechnology Inc., Ltd. · not yet recruiting · Multiple Myeloma in Relapse, Multiple Myeloma Refractory · principal investigator
- Ph2NCT06891040 · Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic DermatitisJiangsu vcare pharmaceutical technology co., LTD · completed · Atopic Dermatitis · principal investigator
- Ph2/Ph3NCT06879379 · KPD Consolidation After ASCT in NDMM PatientsPeking University People's Hospital · recruiting · Multiple Myeloma, Newly Diagnosed · principal investigator
- N/ANCT06699394 · Prospective Study of Teclistamab in the Treatment of Systemic AL AmyloidosisPeking University People's Hospital · recruiting · AL Amyloidosis · principal investigator
- Ph1NCT06655519 · An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaPeking University People's Hospital · not yet recruiting · Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia · principal investigator
- Ph2NCT06418477 · Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDDPeking University People's Hospital · recruiting · Monoclonal Gammopathy of Renal Significance · principal investigator
- N/ANCT06369935 · A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.Peking University People's Hospital · not yet recruiting · Relapsed/Refractory Multiple Myeloma · principal investigator
- Ph2NCT06342466 · Bortezomib, Pomalidomide, Dexamethasone for Systemic AL AmyloidosisJin Lu, MD · recruiting · Systemic Amyloidosis · principal investigator
- N/ANCT06192979 · Optimize First-line Treatment for AL Amyloidosis With t (11; 14)Jin Lu, MD · recruiting · Amyloidosis; Systemic, AL Amyloidosis · principal investigator
- Ph1/Ph2NCT06049290 · A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaNanjing Leads Biolabs Co.,Ltd · recruiting · Relapsed/Refractory Multiple Myeloma · principal investigator
- N/ANCT05831865 · Frontline of ASCT in High-risk DLBCLPeking University People's Hospital · recruiting · Diffuse Large B Cell Lymphoma · principal investigator
- Ph2NCT05478993 · Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS InvolvementPeking University People's Hospital · unknown · Multiple Myeloma · principal investigator
- Ph1NCT05438394 · Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MMPeking University People's Hospital · unknown · Multiple Myeloma · principal investigator
- Ph3NCT04939142 · A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)Antengene Corporation · completed · Relapsed or Refractory Multiple Myeloma · principal investigator
- Ph2NCT02544789 · Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic LeukemiaBetta Pharmaceuticals Co., Ltd. · completed · Acute Lymphoblastic Leukemia · study chair
- Ph4NCT01868828 · A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple MyelomaPeking University People's Hospital · unknown · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 16 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:52 UTC. The ranking covers the 200 most relevant of 990 PubMed records, and a shared surname and initials can bring in a namesake. All 990 on PubMed
- 689 citationsRCR 34.6
- 672 citationsRCR 39.0
- 670 citationsRCR 45.8
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.N Engl J Med · 2021576 citationsRCR 38.2
- Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.N Engl J Med · 2021442 citationsRCR 26.2
- 358 citationsRCR 18.5
- 306 citationsRCR 18.8
- Live Birth with or without Preimplantation Genetic Testing for Aneuploidy.N Engl J Med · 2021280 citationsRCR 21.8
- 243 citationsRCR 37.3
- 233 citationsRCR 19.9